Trial · NCT07390565
YSQTG Combined With Immuno-chemotherapy for Extensive-Stage Small Cell Lung Cancer
NCT07390565, Not applicable, Enrolling by invitation, LI FENG
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. YSQTG Combined With Immuno-chemotherapy for Extensive-Stage Small Cell Lung Cancer. Trials, record NCT07390565. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07390565
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- YSQTG Combined With Immuno-chemotherapy for Extensive-Stage Small Cell Lung Cancer
- NCT number
- NCT07390565
- Status
- Enrolling by invitation
- Phases
- Not applicable
- Enrollment
- 308 participants, estimated
- Lead sponsor
- LI FENG
- Conditions
- Extensive-stage Small Cell Lung Cancer (SCLC)
- Interventions
- Yishen Qutong Granules, Yishen Qutong Simulant Granules
- First posted
- 2026-02-05
- Last updated
- 2026-02-09
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Disease Control Rate（DCR） | Follow-up visits were conducted at 43 days, 90 days, 133 days, 233 days, 365 days (12 months), 450 days (15 months), and 540 days (18 months) after commencement, totalling seven visits. | Disease Control Rate (DCR) = (Complete Response + Partial Response + Stable Disease) /Total Number of Patients × 100% |
| Secondary | Overall Survival（OS） | Before treatment commencement; 21 days after commencement; 43 days after; 90 days after; 133 days after; 233 days after; 365 days after; 450 days after; 540 days after | The period from the commencement of treatment until the patient's death from any cause |
| Secondary | progression-free survival（PFS） | Before treatment commencement; 21 days after commencement; 43 days after; 90 days after; 133 days after; 233 days after; 365 days after; 450 days after; 540 days after | Time from study entry to first radiographic evidence of tumour progression |
| Secondary | Evaluation of Syndrome and Symptom Points of Traditional Chinese Medicine | Before treatment commencement, and at 21 days, 43 days, and 90 days after commencement | The TCM Syndrome Score evaluates the severity of symptoms related to nodule accumulation, localized pain, tongue appearance, lumbar debility, and fatigue. Each symptom is scored from 0 to 6, with higher scores indicating more severe symptoms. The total score is the sum of individual symptom scores, reflecting the overall severity of TCM syndromes. |
| Secondary | Quality of Life assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Before treatment commencement, and at 21 days, 43 days, and 90 days after commencement | The EORTC QLQ-C30 is a 30-item questionnaire evaluating cancer patients' quality of life across multiple dimensions, including physical, emotional, cognitive, and social functioning, as well as symptom burden (e.g., fatigue, pain, nausea). Scores range from 0 to 100, with higher scores in functional scales and global health status indicating better quality of life, and higher scores in symptom scales indicating worse symptoms. |
| Secondary | St George' s Respiratory Questionnaire (SGRQ) | Before treatment commencement, and at 21 days, 43 days, and 90 days after commencement | The St George's Respiratory Questionnaire (SGRQ) is a standardised self-assessment tool used to evaluate the quality of life in patients with chronic respiratory diseases. By quantifying the impairment experienced by patients in terms of symptoms, functional capacity, and psychosocial adjustment, it comprehensively reflects the impact of the disease on patients' daily lives. Scale Range and Interpretation Total score range: 0 to 100. Higher scores indicate greater impairment of health-related quality of life due to respiratory symptoms. |
| Secondary | Fatigue-Related Quality of Life (FACIT-F scale) | Before treatment commencement, and at 21 days, 43 days, and 90 days after commencement | Cancer-related fatigue was assessed using the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) scale. Scale Range and Interpretation Total score range: 0 to 52. Higher scores indicate better fatigue-related quality of life (i.e., less fatigue and its impact). |
| Secondary | Brief Fatigue Inventory scale (BFI scale) | Before treatment commencement, and at 21 days, 43 days, and 90 days after commencement | Fatigue severity was assessed using the Brief Fatigue Inventory (BFI) scale. Scale Range and Interpretation Total score range: 0 to 10. Higher scores indicate more severe fatigue. |
| Secondary | Anxiety subscale of the Hospital Anxiety and Depression Scale (HADS-A) | Before treatment commencement, and at 21 days, 43 days, and 90 days after commencement | Anxiety was assessed using the Anxiety subscale of the Hospital Anxiety and Depression Scale (HADS-A). Scale Range and Interpretation Total score range: 0 to 21. Higher scores indicate more severe anxiety symptoms. |
| Secondary | Depression subscale of the Hospital Anxiety and Depression Scale (HADS-D) | Before treatment commencement, and at 21 days, 43 days, and 90 days after commencement | Depression was assessed using the Depression subscale of the Hospital Anxiety and Depression Scale (HADS-D). Scale Range and Interpretation Total score range: 0 to 21. Higher scores indicate more severe depressive symptoms. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers8
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07390565
GET https://conductscience.org/api/trials/v1/NCT07390565/registered